ALXN US0153511094

End-of-day quote Nasdaq - 07-19
182.50	USD		+1.70%

05/05	Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder	AQ
04/28	Ultomiris approved in the US for adults with generalised myasthenia gravis	AQ
04/26	BREAKING PMPRB NEWS : Another Win For Patients And The Innovative Pharmaceutical Industry	AQ

Summary

Quotes 5-day view End-of-day quote.

End-of-day quote Nasdaq

07/14/2021	07/15/2021	07/16/2021	07/19/2021	07/20/2021	Date
186.61	180.51	180.03	179.45	182.5	Last
8296251	8410329	10300620	10068090	90506120	Volume
+0.34%	-3.27%	-0.27%	-0.32%	+1.70%	Change

Company

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on discovering, development and commercialization of medicines. The Companyâ€™s marketed products include ULTOMIRIS, SOLIRIS (eculizumab), STRENSIQ (asfotase alfa), KANUMA (sebelipase alfa) and ANDEXXA (coagulation Factor Xa - [recombinant] inactivated-zhzo). Its ULTOMIRIS product is a long-acting C5 inhibitor, that works by...

Sector

Pharmaceuticals

Calendar

More about the company

Ratings of Alexion Pharmaceuticals, Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

B-

More Ratings

All news about ALEXION PHARMACEUTICALS, INC.

05/05	Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromy..	AQ
04/28	Ultomiris approved in the US for adults with generalised myasthenia gravis	AQ
04/26	BREAKING PMPRB NEWS : Another Win For Patients And The Innovative Pharmaceutical Industry	AQ
04/11	PMPRB UPDATE : PMPRB Is Accepting Intervener Leave Applications For SOLIRIS Re-hearing	AQ
03/31	SCC Leave Denied In Alexion Pharmaceuticals Inc v Canada (Attorney General)	AQ
03/29	PMPRB UPDATE : Supreme Court Refuses To Hear Appeal From Decision Restricting Canada's Pat..	AQ
03/18	Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litig..	AQ
03/17	AstraZeneca reaches settlement agreement resolving patent litigation related to Ultomir..	AQ
03/01	AstraZeneca and Neurimmune close exclusive global collaboration and licence agreement t..	AQ
03/01	Alexion, Astrazeneca's Rare Disease Group and Neurimmune Closes Deal for Commercializin..	CI
02/10	AstraZeneca sees $4B in COVID vaccine sales as revenue soars	AQ
02/07	PRIORITY NEWS : Referral To EBA Gives PCT Joint Applicants Reasons To Rejoice In 2022	AQ
01/25	The 2022 PMPRB Outlook For Pharmaceutical Patentees In Canada	AQ
01/10	AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to..	AQ
01/07	AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to..	AQ

More news

News in other languages on ALEXION PHARMACEUTICALS, INC.

04/29	ASTRAZENECA : bénéfice lesté de charges exceptionnelles
04/29	ASTRAZENECA : bénéfice lesté de charges exceptionnelles début 2022
03/01	Alexion, le groupe maladies rares d'Astrazeneca et Neurimmune concluent un accord pour ..
02/10	ASTRAZENECA : les recettes liées au Covid vont reculer après une année "record"
02/10	ASTRAZENECA : le rachat d'Actelion a étouffé la rentabilité en 2021

More news

Analyst Recommendations on ALEXION PHARMACEUTICALS, INC.

2021	ALEXION PHARMACEUTICALS : Oppenheimer Upgrades Alexion Pharmaceuticals to Outperform From ..	MT
2021	ALEXION PHARMACEUTICALS : SVB Leerink Adjusts Alexion Pharmaceuticals PT to $173 From $156..	MT
2021	ALEXION PHARMACEUTICALS : SVB Leerink Downgrades Alexion Pharmaceuticals to Market Perform..	MT

More recommendations

Analysis

Exclusive - AstraZeneca exploring options for COVID-19 vaccine business - executive